Literature DB >> 1720370

Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline.

J C Ruckdeschel1, D Moores, J Y Lee, L H Einhorn, I Mandelbaum, J Koeller, G R Weiss, M Losada, J H Keller.   

Abstract

Between December 1985 and August 1988, there were 115 patients at 13 centers who were entered on a randomized comparison of tetracycline and bleomycin for treatment of malignant pleural effusions. Fifteen patients were not treated, primarily due to rapid progression of systemic cancer. Fifteen patients entered on a high-dose regimen of bleomycin (120 units) were excluded from this analysis (following early closure of that arm), leaving 85 patients randomized to low-dose bleomycin (60 units; 44 patients) or tetracycline (1 g; 41 patients). Patients were required to have a cytologically positive pleural effusion, good performance status (0, 1, or 2), lung reexpansion following tube thoracostomy with drainage rates of 100 ml/24 or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent (four weeks) change in systemic therapy. A total of 11 patients (five with bleomycin and six with tetracycline) were not evaluable due to technical problems with tube drainage (one), loss to follow-up (two), sudden death due to pulmonary embolus (one), and rapid progression of systemic disease (seven). There were no clinically significant differences in demographic factors, primary site, performance status, or presence of metastases other than pleural effusion. Overall survival did not differ between the two groups. Median time to recurrence or progression of the effusion was 32 days for tetracycline-treated patients and at least 46 days for bleomycin-treated patients (p = 0.037). The recurrence rate within 30 days of instillation was 36 percent (10/28) with bleomycin and 67 percent (18/27) with tetracycline (p = 0.023) (not all patients were restudied in the first 30 days). By 90 days the corresponding recurrence rates were 30 percent (11/37) for bleomycin and 53 percent (19/36) for tetracycline (p = 0.047). Toxicity was similar between groups.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720370     DOI: 10.1378/chest.100.6.1528

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Management of malignant pleural effusion.

Authors:  P T Reid; R M Rudd
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

3.  Minimally invasive surgical treatment of malignant pleural effusions.

Authors:  Adrian Ciuche; Claudiu Nistor; Daniel Pantile; Teodor Prof Horvat
Journal:  Maedica (Buchar)       Date:  2011-10

Review 4.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

5.  Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.

Authors:  R W Light; N S Wang; J A Despars; S E Gruer; C Sassoon; F S Vargas
Journal:  Lung       Date:  1996       Impact factor: 2.584

Review 6.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

7.  Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.

Authors:  Fabio José Haddad; Riad Naim Younes; Jefferson Luiz Gross; Daniel Deheinzelin
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

8.  Parietal pleurectomy for malignant pleural effusion.

Authors:  W A Fry; J D Khandekar
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

9.  A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusions.

Authors:  A Bhatia; T W Rice; D McLain; P Herzog; G T Budd; S Murthy; T J Kirby; R M Bukowski
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions.

Authors:  A G Villanueva; A W Gray; D M Shahian; W A Williamson; J F Beamis
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.